To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Retrieved from the GovBot source 9/23/2026, 12:51:31 PM (UTC). Viewing this record does not change stored data.
At a glance
- Bill number
- HR 1051
- Status
- Not provided
- Latest recorded action
- Referred to the House Committee on Energy and Commerce.
Summary
Not provided in this source record.
Recorded activity
Newest date first. Actions with the same timestamp retain source order.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Retrieval & source record
- Search index built (UTC)
- 2026-09-07T10:23:11.520Z
- Dataset
- govbot-data/usa-legislation
- Retrieved (UTC)
- 2026-09-23T12:51:31.091Z
- Live source branch
- main (mutable; checksum identifies the retrieved record)
- Search index revision
b5b4a6d28d2dd595bb5724470458ffceaf19bcb7- Original record
- View GovBot metadata JSON (opens in a new tab)
- Record SHA-256
77d9b96febd906c3b587e0c93ca64d5f3249a2f2c936824094ad905e8c5c1572